Humanized Antibody Inhibiting Amyloid Beta Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating amyloidosis, particularly Alzheimer's disease and age-related macular degeneration, are inadequate as they fail to effectively prevent or reverse the formation of amyloid plaques and do not provide long-term solutions, with existing treatments having modest effects and significant side effects.
Innovation Solution
Development of highly specific and effective chimeric or humanized antibodies that recognize and bind to specific epitopes on the β-amyloid protein, capable of inhibiting the aggregation of amyloid monomers into fibrils and disaggregating preformed fibrils, thereby reducing amyloid plaque burden.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diagnostic and treatment methods are used for amyloidosis, then the disease can be diagnosed and treated, but the treatments fail to effectively prevent or reverse amyloid plaque formation and have only modest effects with significant side effects
Solution Approach 1:
The patent employs antibodies as intermediary molecules that specifically bind to amyloid-beta aggregates. These antibodies act as mediators between the immune system and the amyloid plaques, enabling targeted recognition and clearance of pathological deposits without affecting normal physiological processes, thereby achieving effective treatment with reduced side effects
Solution Approach 2:
The invention utilizes antibodies with specifically engineered binding parameters and affinities for amyloid-beta aggregates. By optimizing the binding characteristics of the antibodies through molecular design and selection, the treatment achieves enhanced effectiveness in preventing and reversing plaque formation while maintaining safety profiles
2Duration of action of stationary object
If existing treatments are administered, then some therapeutic effect is achieved, but they do not provide long-term solutions and amyloid plaque formation continues
Solution Approach 1:
The patent employs antibodies that prevent amyloid plaque formation by binding to amyloid-beta monomers and oligomers before they can aggregate into insoluble plaques. This preliminary intervention stops the pathological process at early stages, providing long-term protection and sustained therapeutic effects that address the root cause rather than just symptoms
Solution Approach 2:
The invention enables continuous therapeutic action through antibodies that maintain persistent binding to amyloid-beta aggregates, preventing further aggregation and facilitating ongoing clearance. This continuous mechanism ensures sustained reduction of plaque burden over time, providing durable long-term solutions
3Reliability
If antibodies are developed to bind to multiple distinct binding sites on beta-amyloid, then the effectiveness against amyloid aggregates is enhanced, but the complexity of antibody design and production increases
Solution Approach 1:
The patent employs antibodies that recognize and bind to multiple distinct epitopes or binding sites on the amyloid-beta protein. This segmentation of recognition targets across different regions of the amyloid aggregate provides enhanced binding stability and effectiveness, while the modular nature of antibody-antigen interactions facilitates rational design approaches
Solution Approach 2:
The invention utilizes antibodies with multi-functional capabilities that can bind to various conformations and aggregates of amyloid-beta (monomers, oligomers, fibrils, and plaques). This universality allows a single antibody design to address multiple forms of amyloid pathology, enhancing effectiveness while streamlining development through a platform approach
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.